CA3174455A1 - Therapeutic uses of macrocyclic compounds - Google Patents
Therapeutic uses of macrocyclic compoundsInfo
- Publication number
- CA3174455A1 CA3174455A1 CA3174455A CA3174455A CA3174455A1 CA 3174455 A1 CA3174455 A1 CA 3174455A1 CA 3174455 A CA3174455 A CA 3174455A CA 3174455 A CA3174455 A CA 3174455A CA 3174455 A1 CA3174455 A1 CA 3174455A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- carcinoma
- met
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| US62/984,159 | 2020-03-02 | ||
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174455A1 true CA3174455A1 (en) | 2021-09-10 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174455A Pending CA3174455A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (https=) |
| EP (1) | EP4114530A4 (https=) |
| JP (1) | JP2023515687A (https=) |
| KR (1) | KR20230022151A (https=) |
| CN (1) | CN115397514A (https=) |
| AU (1) | AU2021229457A1 (https=) |
| BR (1) | BR112022017425A2 (https=) |
| CA (1) | CA3174455A1 (https=) |
| IL (1) | IL295938A (https=) |
| MX (1) | MX2022010945A (https=) |
| WO (1) | WO2021178296A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| RU2765181C2 (ru) * | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| US10689400B2 (en) * | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt unknown
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko active Pending
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250262216A1 (en) | 2025-08-21 |
| AU2021229457A1 (en) | 2022-10-20 |
| IL295938A (en) | 2022-10-01 |
| CN115397514A (zh) | 2022-11-25 |
| BR112022017425A2 (pt) | 2022-11-29 |
| EP4114530A4 (en) | 2024-04-17 |
| MX2022010945A (es) | 2022-10-07 |
| WO2021178296A1 (en) | 2021-09-10 |
| KR20230022151A (ko) | 2023-02-14 |
| JP2023515687A (ja) | 2023-04-13 |
| EP4114530A1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12310968B2 (en) | Chiral diaryl macrocycles and uses thereof | |
| WO2022212894A1 (en) | Methods for inhibiting ras | |
| US9657008B2 (en) | Chemical compounds | |
| US8937095B2 (en) | Anticancer compounds | |
| US20140194442A1 (en) | Anticancer therapy | |
| US20140018372A1 (en) | Crystalline form of a indolinone derivative and its use | |
| US20190183880A1 (en) | Method of inhibiting mutant c-kit | |
| CA3174455A1 (en) | Therapeutic uses of macrocyclic compounds | |
| US20230241052A1 (en) | Method of inhibiting mutant c-kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250826 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260413 |